derisk lrp remain
guidanc line expect manag
commentari derisk lrp achiev without
larg custom contract remain convinc nexsi
thesi remain overweight pt
commentari derisk lrp haemonet report
revenu vs mse gross margin declin q/q result
higher nexsi depreci less concern given gross margin
leverag impli guidanc price continu leverag ramp opex
disciplin primari driver ep beat vs mse
guidanc organ growth includ plasma growth
line preview ep expect
in-line model investor perceiv guidanc
binari risk quarter combin manag commentari lrp
long rang plan discuss like view clear event
lrp derisk larg custom contract need plasma
guidanc emb north america na plasma market growth low-
teen vs includ current sign contract haemonet
track meet lrp target plasma revenu
current sign contract faster market growth alon larg custom
contract could sign later year would provid upsid
number regardless manag sound much better structur
outlook busi blood center hospit look track
behind lrp goal though note anniversari contract exit next year
teg trauma indic submit last quarter help respect
regard profit manag indic haemonet meet ebit
lrp target without new plasma contract remain construct
ep growth derisk stori limit downsid
risk investor think close later year
great plasma debat specif disclosur nexsi limit
manag continu express confid system valu proposit
model plasma growth year upper end guidanc
assum minim new system placement nexsi price drive pt growth
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
model similar expect compani anniversari system
placement price arrang throughout year continu
model nexsi deliv premium plasma item flag
inventori inventori balanc sheet increas q/q
largest sequenti increas last quarter
averag minim sequenti inventori chang
driven consum volum larg portion like driven
nexsi see posit develop around futur demand
exist custom experi
custom dilig exist potenti custom dilig quarter
favor cost yield benefit nexsi dilig
potenti futur custom remain posit cost softwar yield
on-going center trial focus patient experi
addit contract larg addit contract remain import
debat guidanc derisk dilig suggest appreci
nexsi valu continu build model assum
addit contract year custom dilig suggest larg
contract decis could come
guidanc larg consist model guidanc larg
line preview continu model plasma guidanc top
end guidanc discuss lower blood center estim
declin line updat guidanc account upcom contract
exit rais hospit growth estim lower end
guidanc given histor teg traction difficulti note could area
upsid trauma indic year organ growth estim
move midpoint guidanc net model
oper margin ep estim move upper rang
guidanc confid core busi drop sustain
manag confid handl manufactur logist
issu pressur result new notabl given manag
track record execut visibl complex reduct initi
save see like manag achiev upper end
guidanc came line investor expect eas concern
plasma manag derisk origin lrp achiev current
contract could quantifi downsid risk ahead potenti larg
contract time later year remain confid nexsi remain
primari driver overweight thesi addit
lever deploy beyond nexsi includ teg oper leverag via
tuck-in balanc sheet deploy continu see path
exceed compani lrp continu model ebit
compani target price target move modestli
continu reflect ebitda estim includ quarter
contribut remain overweight
haemonet nexsi drive transform stori
haemonet nexsi drive transform stori
price target reflect ev/ebitda
estim premium smid cap peer
upsid nexsi price complex reduct initi dropthrough
balanc sheet option drive ebit achiev
per liter increment plasma price nexsi greater cost
save drop balanc sheet option third parti financ
capit deploy drive materi upsid ebit
nexsi complex reduct initi drive ebit
haemonet abl achiev favor increment plasma price
nexsi save help compani exceed lrp ebit object
nexsi unabl gain materi price benefit nexsi unabl
creat materi valu custom and/or unabl obtain
competit price plasma growth remain line market growth rate
minim cost save drop
stori tie long-
rang plan lrp doubl oper incom
quadrupl turnaround
primarili lever nexsi product
compani next-gener plasma
valu creation materi yield
opportun appreci see
posit backdrop nexsi drive
valu per liter plasma
custom expect share
profit increment per
liter price indic nexsi alon
drive lrp object
complex reduct initi
seek provid cost save
add option de-risk
lrp believ allow haemonet
exceed lrp object
nexsi valu price potenti
drop-through
risk achiev price
benefit nexsi ii identif
addit cost opportun iii capit
downsid risk includ nexsi
disappoint ii cost save fail materi
iii blood bank slow materi iv
million except ep
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
equival
accum comprehens incom
dollar million except per share data
loss asset dispos
chang work capit
net provid oper activ
capit intang asset
sale properti invest
net use invest activ
chang equiti
net financ activ
net chang
equival bop
equival eop
